Insider · CIK 0001639479
Michael Joseph Golembiewski
Files at SEEL (SEELOS THERAPEUTICS, INC.). First filing Dec 1, 2023, latest Dec 1, 2023.
In brief
Michael Joseph Golembiewski files SEC Form 4 as CFO at SEEL (SEELOS THERAPEUTICS, INC.). Since Dec 1, 2023, Michael Joseph Golembiewski has reported 1 open-market buy worth $100k and 0 open-market sells worth $0, the latest filed on Dec 1, 2023.
A track record needs three past buys with six months of prices behind them; Michael Joseph Golembiewski has 0, so none is measured yet.
The newest scored trade: bought $100k of SEEL on Nov 30, 2023, filed Dec 1, 2023, scored 50 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | SEELOS THERAPEUTICS, INC. | $100k 83,000 shares | +2406% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 29, 2024 | SEEL SEELOS THERAPEUTICS, INC. | AGrant or award Common Stock | +417 | $1.10 | $457 | 86,869 | Mar 1, 2024 |
| Jan 12, 2024 | SEEL SEELOS THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +24,537 | $0.00 | $0 | 24,537 | Jan 17, 2024 |
| Nov 30, 2023 | SEEL SEELOS THERAPEUTICS, INC. | POpen-market purchase Common Stock | +83,000 | $1.21 | $100k | 86,450 | Dec 1, 2023 |
Questions about Michael Joseph Golembiewski
Answered from the filings on this page, as of the latest one.
Is Michael Joseph Golembiewski buying or selling?
Not in the last 12 months. Michael Joseph Golembiewski's latest open-market trade on SEC Form 4 was bought $100k of SEEL on Nov 30, 2023.
How did Michael Joseph Golembiewski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Joseph Golembiewski has 0.
Where does Michael Joseph Golembiewski file Form 4?
Michael Joseph Golembiewski has filed Form 4 at SEEL (SEELOS THERAPEUTICS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.